UrgoStart Plus Pad

UrgoStart Plus Pad is effective at every wound healing phase, from the start* and through to complete healing.

This dressing:

• Desloughs and absorbs exudates thanks to its polyabsorbent fibres.
• Reduces healing time thanks to its patented TLC-NOSF** matrix.

The efficacy of TLC-NOSF on the reduction of healing time has been demonstrated in double-blind, randomised controlled clinical studies ^(2,3) and by an analysis of observational studies.⁽⁴⁾ The earlier TLC-NOSF treatment is started, the more effective it is^(3,4).

UrgoStart Plus Pad is highly conformable and can be cut to fit the shape and size of the wound. It is suitable for damaged surrounding skin. It can also be juxtaposed and used under compression.

Finally, UrgoStart Plus Pad is always used as part of a global management approach, along with appropriate etiological treatment.

UrgoStart Plus Pad is a dressing indicated for all healing phases* (from the desloughing phase* through to hea

ling) in the treatment of chronic exuding wounds (leg ulcers, pressure ulcers, diabetic foot ulcers) and acute wounds that have become chronic.

Contraindications:

• UrgoStart Plus Pad helps control minor bleeding. However, it should not be used for heavily bleeding wounds.
• To prevent any risk of delay in appropriate treatment, UrgoStart Plus Pad is contraindicated in cancerous wounds and in wounds demonstrating deep abscess formation.
• Do not use UrgoStart Plus Pad in the event of known sensitivity to the dressing.
•  

. Wound preparation:

• Clean the wound using the conventional care protocol, then rinse with normal saline.
• If an antiseptic has previously been used, rinse the wound carefully with normal saline before applying UrgoStart Plus Pad.
• Carefully dry the skin around the wound.
• The use of UrgoStart Plus Pad does not dispense with the need for mechanical debridement when required.

2. Dressing application:

• Carefully remove the protective tabs.
• Apply with the micro-adherent side of the UrgoStart Plus Pad dressing in contact with the wound. UrgoStart Plus Pad can be cut using sterile scissors to fit the dressing size to the wound if required.
• If necessary, cover with a secondary dressing suitable for the location and exuding nature of the wound.
• Apply a compression bandage over the dressing where prescribed.

3. Dressing removal:

• Pressing on healthy skin, lift a corner of the dressing and remove it carefully.

4. Dressing changes:

• Remove the entire dressing when it is saturated and clean the wound if required. It is recommended that the UrgoStart Plus Pad dressing be changed every 1 to 2 days during the wound desloughing phase, then as often as required by the volume of exudates and the clinical progress of the wound. It can be left in place for up to 7 days.
• Discard any unused parts of the dressing.

Precautions for use:

• The micro-adherent mass of the UrgoStart Plus Pad dressing sticks to latex surgical gloves. Therefore it is recommended that the tabs be used to facilitate application of the dressing.
• If the wound shows signs of local infection, it is recommended that the bacterial component be treated first with an antimicrobial dressing (such as UrgoClean Ag) before starting treatment with UrgoStart Plus Pad.
• In the event of an atypical ulcer demonstrating induration or excessive granulation, treatment with UrgoStart Plus Pad should only be started after having verified the absence of any ulcer deterioration, to prevent any delay in diagnosis.
• In the absence of clinical data in the context of Epidermolysis bullosa (irrespective of its duration), the use of UrgoStart Plus Pad dressings is not recommended.
• Stinging or even painful sensations can be reported at the start of treatment: these are generally related to the healing process and rarely warrant suspension of treatment.
• During desloughing, the wound may appear to get larger due to gradual elimination of slough.
• The concomitant use of a cream, lotion, ointment or emulsion is not recommended.
• Sterile individual packaging, for single use: reuse of a disposable dressing can lead to risks of infection.
• Do not re-sterilise the dressing.
• Check that the sterility protector is intact before use. Do not use if the packaging is damaged.

In 2012, the Journal of Wound Care published the CHALLENGE⁽⁵⁾ study, demonstrating that TLC-NOSF treatment leads to a greater reduction in wound surface area compared to a neutral dressing.

In December 2018, The Lancet Diabetes & Endocrinology international medical journal published the EXPLORER⁽²⁾ clinical trial, demonstrating that TLC-NOSF treatment heals 60% more patients compared to a neutral dressing and that the earlier TLC-NOSF treatment is started, the more effective it is⁽³⁾.

The REALITY⁽⁴⁾ analysis, published in 2017 in the Journal of Wound Care, presents a compilation of eight observational studies conducted in more than 10,000 patients and shows that TLC-NOSF reduces the healing time of chronic wounds by an average of 100 days and that the earlier TLC-NOSF treatment is started, the more effective it is.

In 2020, the Journal of Wound Care published the last URGOSTART PLUS OBSERVATIONAL STUDY conducted in 1,140 patients, demonstrating that UrgoStart Plus is effective irrespective of the wound type, whatever the wound phase and however long it has been present⁽⁶⁾.

The HAS (French National Authority for Health) has granted the entire range a level III clinical added value (CAV)⁽⁷⁾ something that is unprecedented for a dressing.

The URGO Group was awarded the 2018 Galien France medical device prize for UrgoStart^®. Each year, this prestigious award recognises exceptional innovations in the field of health.

In January 2019, the United Kingdom’s NICE (National Institute for Health and Care Excellence) recommended TLC-NOSF treatment for the wound care of diabetic foot ulcers and venous leg ulcers⁽⁸⁾. The NICE recommendations support the fact that the UrgoStart® range has better results in terms of reducing wound healing time, improving patients’ quality of life and enabling significant savings for health authorities compared to neutral dressings.

2019: IWGDF (International Working Group on the Diabetic Foot) guidelines This is the very first time that a dressing has been recommended by the IWGDF⁽⁹⁾.

References:

*Excluding dry necrosis. **TLC-NOSF: Lipido-Colloid technology – Nano OligaSaccharide Factor (KSOS: Potassium octasulfate sucrose salt).

1. Report to the French minister responsible for Social Security and the French Parliament concerning the evolution of French National Health Insurance charges and products for 2014. July 2013. CNAM database: leg ulcers: 210 days; pressure ulcers: 223 days; diabetic foot ulcers: comparative data not available.

2. Edmonds M et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar; 6(3): 186-196.

3. Lázaro-Martínez JL et al. Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. J Wound Care. 2019 Jun 2; 28(6): 358-367.

4. Münter KC et al. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153.

5. Meaume S et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen. 2012; 20(4): 500-511.

6. Dissemond J. et al. Clinical evaluation of polyabsorbent TLC-NOSF dressings on chronic wounds: a prospective, observational, multicentre study of 1140 patients. J Wound Care. 2020; 29(6): 350-361.

7. CAV III: in non-infected (IDSA/IWGDF infection criteria) neuro-ischaemic diabetic foot ulcers (non-critical ischaemia), in the granulation phase (sequential treatment).

8. In leg ulcers and diabetic foot ulcers. https://www.nice.org.uk/guidance/mtg42, January 2019.

9. In the treatment of diabetic foot ulcers. IWGDF Guidelines on the prevention and management of diabetic foot disease, 2019.

UrgoStart Plus Pad: Class IIb medical device (G-Med; 0459). Treatment to reduce healing time. LPPR fully reimbursable (Social Security: 60% + top-up mutual insurance: 40%) in the treatment of venous or mixed, predominantly venous leg ulcers in the granulation phase (sequential treatment), and in non-infected (IDSA/IWGDF infection criteria) neuro-ischaemic diabetic foot ulcers (non-critical ischaemia), in the granulation phase (sequential treatment). Read the leaflet carefully before use, particularly the precautions for use and contraindications.
Manufacturer: Laboratoires URGO – 01/2021.